期刊文献+

人重组pMAGE-A1/EGFP真核表达质粒的构建与表达 被引量:1

Construction and expression of recombinant human eukaryotic expression vector pMAGE-A1/EGFP
下载PDF
导出
摘要 目的 特异克隆MAGE A1开放读码框基因,构建以绿色荧光蛋白(EGFP)为报告基因的包含MAGE A1的真核表达载体并转染人PBMC来源DC细胞。方法 根据MAGE A1特征序列设计PCR扩增引物,从Mel 5 2 6中扩增MAGE A1基因开放读码框,并克隆至pIRES EGFP中,构建人重组pMAGE A1 EGFP真核表达质粒。利用电转染方法将该重组质粒转入人外周血来源DC细胞并检测MAGE A1和EGFP的表达情况。结果 成功构建真核表达质粒pMAGE A1 EGFP ,转染人PBMC来源DC细胞并检测到MAGE A1和EGFP表达,两者表达率分别为(8.8±0 .9) %和(8.4 7±0 .78) % ,无统计学差异。结论 成功构建人重组真核表达质粒pMAGE A1 EGFP ,为开展MAGE A1为基础的免疫治疗提供有利的分子生物学工具。 Objective To clone MAGE-A1 gene open reading frame and construct eukaryotic expression vector with green fluorescent protein, and to transfect human PBMC-derived DCs. Methods MAGE-A1 open reading frame was amplified from Mel-526 by RT-nest PCR with specific primers, and then cloned into eukaryotic expression vector with EGFP. After construction of recombinant plasmid pMAGE-A1/ EGFP, human PBMC-derived DCs were transfected with pMAGE-A1/EGFP by electroporation, and protein expression was identified by fluorescent microscopy. Results The pMAGE-A1/EGFP eukaryotic expression vector was constructed successfully. MAGE-A1 and EGFP were expressed after transfection into DCs. Conclusion The pMAGE-A1/EGFP eukaryotic expression vector will provide a new modality of tumor immunotherapy targeting MAGE-A1 gene.
出处 《免疫学杂志》 CAS CSCD 北大核心 2005年第2期107-110,共4页 Immunological Journal
关键词 MAGE-A1基因 绿色荧光蛋白 基因克隆 真核表达质粒 MAGE-A1 Enhanced green fluorescent protein Gene cloning Gene expression vector
  • 相关文献

参考文献5

  • 1Graft Dubois S, Faure O, Gross DA, et al. Generation of CTL recognizing an HLA-A * 0201-restricted epitope shared by MAGE-A1, -A.2, -A3, -A4, -A6, -A10, and -A12 rumor antigens: implication in a broad-spetrum tumor immunotherapy [J]. J Immunol, 2002, 169 (1): 575- 580.
  • 2金冬雁 黎孟枫 侯云德 译.分子克隆实验指南[M]:2版[M].北京:科学出版社,1999.16-22.
  • 3Thompson JD, Gibson TJ, Plewniak F, et al. The Clustal-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools [J]. Nucleic Acids Res, 1997, 25 (24): 4 876-4 882.
  • 4Imai Y, Shichijo S, Yamada A, et al. Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens [J]. Gene, 1995, 160 (2): 287-290.
  • 5Hennecke M, Kwissa M, Metzger K, et al. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs [J]. Nucleic Acids Res, 2001,29 (16): 3 327 - 3 334.

同被引文献13

  • 1Kim KS,Hong YK,Lee Y,et al.Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains:amino-terminal fragment and kringle domain[J].Exp Mol Med.2003,35(6):578-585.
  • 2Mukhina S,Stepanova V,Traktouev D,et al.The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain.Characterization of interactions and contribution to chemotaxis[J].J Biol Chem,2000,275(22):16 450-16 458.
  • 3Kim KS,Hong YK,Joe YA,et al.Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells[J].J Biol Chem,2003,278(13):11 449-l1 456.
  • 4Blasi F,Vassalli JD,Dano K.Urokinase-type plasminogen activator:proenzyme,receptor,and inhibitors[J].J Cel Biol,1987,104(4):801-804.
  • 5Belin D,Vassalli JD,Combepine C,et al.Cloning,nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator[J].Eur J Biochem,1985,148(2):225-232.
  • 6Duffy MJ.The urokinase plasminogen activator system:role in malignancy[J].Curr Pharm Des,2004,10(1):39-49.
  • 7Lefesvre P,Attema J,van Bekkum D.Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth[J].BMC Cancer,2002,2:17.
  • 8Mohanam S,Chandrasekar N,Yanamandra N,et al.Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator[J].Oncogene,2002,21(51):7 824-7 830.
  • 9Wada M,Wada NA,Shirono H,et al.Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication[J].Biochem Biophys Res Commun,2001,284(2):346-351.
  • 10Le Gat L,Gogat K,Bouquet C,et al.In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy[J].Gene Ther,2003,10(25):2 098-2 103.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部